" class="no-js "lang="en-US"> NuvoAir Respiratory Platform Shows Promise for Long-Term Remote Monitoring of Asthma - Medtech Alert
Tuesday, April 23, 2024

NuvoAir Respiratory Platform Shows Promise for Long-Term Remote Monitoring of Asthma

Three new studies show how home monitoring technology – developed by leading digital health company NuvoAir – can be successfully used by both adults and children living with asthma. These findings pave the way for improved treatment and management opportunities for people with asthma.

The studies presented at the American Thoracic Society 2021 International Conference demonstrate how patients with asthma are able to produce high-quality lung function test results when using the NuvoAir Home platform. Patients also showed high adherence to home monitoring using the platform with impressive levels of satisfaction reported.

Asthma presents a considerable burden to patients, healthcare and society at large. Missed diagnosis, incorrect treatment and poor self-management of asthma contribute to an estimated $81.9 billion cost to society a year in the U.S., and £6.2 billion a year in the UK. While self-management is considered key to controlling asthma and staying out of the hospital, manual self-monitoring with written diaries is not popular with patients.

NuvoAir provides a human-led digital care management platform that allows people with respiratory conditions to monitor their condition from home and share results in real-time with their healthcare providers and NuvoAir Care Coordinators. The platform offers a patient app with connected devices, self-management content, care coordination services, and a healthcare provider portal. The provider portal enables healthcare teams to monitor patient data remotely and identify worsening respiratory health in real-time so that rapid interventions can be made. Connected devices include a Bluetooth-enabled spirometer to remotely monitor lung function; a sensor that attaches to asthma and COPD inhalers to monitor adherence and technique; a nighttime cough monitoring app and an activity tracker.

NuvoAir’s CEO Lorenzo Consoli shared, “Two fundamental aspects of any successful digital health tool are whether it can be used effectively by patients at home and whether patients want to use it on a long-term basis. We welcome these study findings that help show how NuvoAir can empower people with asthma to spot deteriorations and better manage their condition from home while allowing clinical teams to monitor their progress from a distance.”

Published clinical evidence and peer-reviewed studies demonstrating NuvoAir’s clinical impact, technological validity, and high patient satisfaction with patients across respiratory conditions can be found on NuvoAir’s website. 

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more